Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Cavazide
Rx75 mg+12.5 mg • Tablet
Indications & Uses
This tablet is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
A patient whose blood pressure is inadequately controlled by irbesartan or Hydrochlorothiazide alone may be switched to once daily to minimize dose independent side effects. Recommended doses are (irbesartan and hydrochlorothiazide) 150-12.5 mg (one 150 tablet), 300-12.5 mg (one 300 tablet), and 300-25 mg (two 150 tablet). The largest incremental effect will likely be in the transition from monotherapy to 150-12.5 mg (one 150 tablet). It takes 2-4 weeks for the blood pressure to stabilize after a change in the dose of this tablet. The usual dose- 150 is one tablet once daily More than two tablets once daily is not recommended. The maximal antihypertensive effect is attained about 2-4 weeks after initiation of therapy.Use in Patients with Renal Impairment: The usual regimens of therapy may be followed as long as the patient’s creatinine clearance iss 30 mVmin. Patients with Hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment.
Side Effects
Gastro-intestinal system: Anorexia, gastric irritation, nausea, vomiting, cramps, diarrhoea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, salivary gland inflammation. Central nen/ous system: Dizziness, vertigo, headache, yellow vision.Cardiovascular: Subjective rhythm disturbance, flushing, ECG abnormality cardiac murmur, cardiac rhythm disturbance, orthostatic hypotension, atrial rhythm disturbance, bradycardia, hypotension, syncope, conduction disorder, myocardial infarction.
Cautions & Contraindications
Warnings & Precautions
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function depends on the activity of the renin-angiotensin- aldosterone system (e.g. hypertensive patients with renal artery stenosis in one or both kidneys, or patients with severe congestive heart failure), treatment with drugs that affect this system has been associated with oliguria andlor progressive azotemia and (rarely) with acute renal failure andlor death. The possibility of a similar effect occurring with the use of an angiotensin ll receptor antagonist, including irbesartan, cannot be excluded. Experience is limited with irbesartan in patients with moderate to severe renal impairment; careful monitoring of renal function and potassium in such patients is advised. While hyperkalaemia in uncomplicated patients with hypertension has not been reported with irbesartan, hyperkalaemia may occur during treatment with other drugs that affect the renin-angiotensin-aldosterone system, especially in the presence of renal impairment and/or heart failure. Adequate monitoring of serum potassium in patients at risk is recommended. The safety of irbesartan in the presence of heart failure has not been fully defined. Sudden death has oocuned in some studies of patients with heart failure, and although such deaths may have reflected the natural history of the underlying heart failure, caution is recommended when treating such patients with irbesartan. At this time, experience is limited with irbesartan in the treatment of patients with ventricular dysfunction or cardiac arrythmias; caution is advised.
Contraindications
irbesartan and Hydrochlorothiazide tablet is contra-indicated in patients who are hypersensitive to irbesartan, Hydrochlorothiazide, and in pregnancy.